Live

V

$VTRS

4 articles found

3 positive

0 negative

1 neutral

Opus Genetics to Present Phase 3 Presbyopia Data at Major Eye Surgery Conference

GlobeNewswire Inc.

GlobeNewswire Inc.·Apr 10·Na

Opus Genetics to Present Phase 3 Presbyopia Data at Major Eye Surgery Conference

Opus Genetics will present three abstracts at ASCRS 2026, including Phase 3 results for phentolamine ophthalmic solution treating presbyopia and mesopic vision issues.

VTRSIRDPhase 3 clinical trialgene therapy

Viatris Stock Trading Below Fair Value With 13.5% FCF Yield and Growth Catalysts Ahead

Investing.com

Investing.com·Apr 2·Gurufocus

Viatris Stock Trading Below Fair Value With 13.5% FCF Yield and Growth Catalysts Ahead

Viatris trades 17% below peers despite 13.5% FCF yield and $2.2B annual cash generation. Growth catalysts and cost-savings program launching 2026 suggest significant upside.

VTRSTEVAshare buybacksEBITDA growth

SLE Drug Race Heats Up: 120+ Pharma Giants Develop 140+ Pipeline Therapies

GlobeNewswire Inc.

GlobeNewswire Inc.·Apr 1·Delveinsight

SLE Drug Race Heats Up: 120+ Pharma Giants Develop 140+ Pipeline Therapies

Over 120 pharmaceutical companies are developing 140+ drugs for systemic lupus erythematosus, with major players like Roche and Novartis advancing promising new treatment mechanisms.

JNJABBVNVSRHHBYAZN+3FDA approvalclinical trials

Viatris Reaffirms Annual Dividend Commitment With $0.48 Per Share Policy

Benzinga

Benzinga·Feb 26·Prnewswire

Viatris Reaffirms Annual Dividend Commitment With $0.48 Per Share Policy

Viatris reaffirms $0.48 annual dividend per share for 2026, declaring $0.12 quarterly payout. Marks sixth consecutive year of consistent shareholder distributions.

VTRSquarterly dividendshareholder returns